Okabena Investment Services Inc. Takes Position in Cryoport, Inc. (NASDAQ:CYRX)

Okabena Investment Services Inc. purchased a new position in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 79,072 shares of the company's stock, valued at approximately $615,000. Okabena Investment Services Inc. owned 0.16% of Cryoport as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also bought and sold shares of the business. Rhumbline Advisers grew its holdings in shares of Cryoport by 2.9% during the 4th quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock worth $492,000 after purchasing an additional 1,764 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Cryoport by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company's stock worth $3,144,000 after buying an additional 2,226 shares in the last quarter. Penbrook Management LLC grew its stake in Cryoport by 6.0% during the fourth quarter. Penbrook Management LLC now owns 52,570 shares of the company's stock worth $409,000 after buying an additional 2,975 shares in the last quarter. American Century Companies Inc. increased its holdings in Cryoport by 12.0% in the 4th quarter. American Century Companies Inc. now owns 51,443 shares of the company's stock valued at $400,000 after buying an additional 5,508 shares during the period. Finally, Avanza Fonder AB acquired a new position in shares of Cryoport in the 4th quarter valued at approximately $64,000. 92.90% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.29, for a total transaction of $29,059.80. Following the transaction, the chief executive officer now directly owns 765,399 shares of the company's stock, valued at approximately $4,814,359.71. The trade was a 0.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 19,830 shares of company stock valued at $118,353 in the last ninety days. 10.10% of the stock is currently owned by insiders.

Remove Ads

Cryoport Price Performance

Shares of NASDAQ CYRX traded up $0.08 during mid-day trading on Wednesday, hitting $6.17. 210,411 shares of the stock traded hands, compared to its average volume of 416,488. The company has a market cap of $307.94 million, a PE ratio of -1.83 and a beta of 1.67. Cryoport, Inc. has a twelve month low of $4.58 and a twelve month high of $20.10. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. The firm has a 50 day simple moving average of $6.61 and a two-hundred day simple moving average of $7.28.

Cryoport (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.09). The firm had revenue of $59.53 million for the quarter, compared to analyst estimates of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same period in the previous year, the business posted ($0.29) earnings per share. As a group, equities research analysts forecast that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CYRX. UBS Group lifted their price objective on shares of Cryoport from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Tuesday. Roth Mkm reiterated a "buy" rating and issued a $15.00 price target on shares of Cryoport in a research note on Tuesday. Needham & Company LLC restated a "buy" rating and set a $11.00 price objective on shares of Cryoport in a research report on Monday. Finally, Guggenheim assumed coverage on Cryoport in a research report on Thursday, December 19th. They issued a "buy" rating and a $11.00 target price on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Cryoport currently has an average rating of "Moderate Buy" and an average target price of $11.83.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.